Conference Proceedings

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in >= 2 line recurrent or metastatic cervical cancer

KS Tewari, BJ Monk, A Oaknin, S Lheureux, F Zagouri, D Rischin, K Hasegawa, YM Kim, R Pereira, A Sadozye, PH Wang, A Lisyanskaya, V Samouelian, HS Kim, M Zambrano, S Yi, J Li, M Feng, M Mathias, MG Fury Show all

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2020